🇺🇸 FDA
Patent

US 11414439

Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

granted A61KA61K31/404A61K31/47

Quick answer

US patent 11414439 (Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator) held by Vertex Pharmaceuticals Incorporated expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K31/404, A61K31/47, A61K31/695, A61P